Hematopoiesis News Volume 7.22 | Jun 7 2016

TOP STORY

Jmjd2/Kdm4 Demethylases Are Required for Expression of Il3ra and Survival of Acute Myeloid Leukemia Cells

Researchers demonstrated that expression of the interleukin 3 receptor α (Il3ra also known as Cd123) subunit is dependent on Jmjd2/Kdm4 through a mechanism involving removal of H3K9me3 from the promoter of the Il3ra gene. [Genes Dev] Abstract

(Ranked by impact factor of the journal)

JAK2V617F-Mutant Megakaryocytes Contribute to Hematopoietic Stem/Progenitor Cell Expansion in a Model of Murine Myeloproliferation

The authors report here that mice bearing a human JAK2V617F gene restricted exclusively to the megakaryocyte lineage develop many of the features of a myeloproliferative neoplasms. [Leukemia] Abstract

Loss of Dnmt3b Accelerates MLL-AF9 Leukemia Progression

Scientists demonstrated that deletion of Dnmt3b accelerated the progression of MLL-AF9 leukemia by increasing stemness and enhancing cell cycle progression. [Leukemia] Abstract

Heterogeneous Nuclear Ribonucleoprotein L Is Required for the Survival and Functional Integrity of Murine Hematopoietic Stem Cells

Researchers report that the splice factor and RNA binding protein heterogeneous nuclear ribonucleoprotein L is required for hematopoiesis, since its genetic ablation in mice reduced almost all blood cell lineages and caused premature death of the animals. [Sci Rep] Full Article

EphrinB2 Regulates the Emergence of a Hemogenic Endothelium from the Aorta

Investigators showed that EphrinB2, a principal regulator of endothelial cell function, controls the development of endothelium producing adult-type hematopoiesis. [Sci Rep] Full Article

Sepsis Induces Hematopoietic Stem Cell Exhaustion and Myelosuppression through Distinct Contributions of TRIF and MYD88

Using mice deficient in toll-like receptor 4 downstream adapters MYD88 or TRIF, researchers demonstrated that both cell-autonomous and non-cell-autonomous MYD88 activation are major causes of myelosuppression during sepsis, while having a modest impact on hematopoietic stem cell functions. [Stem Cell Reports] Full Article | Graphical Abstract

The Spliceosomal Component Sf3b1 Is Essential for Hematopoietic Differentiation in Zebrafish

Using zebrafish mutants, investigators showed that proper function of Sf3b1 (Splicing factor 3b, subunit 1) is required for all hematopoietic lineages. Similar to myelodysplastic syndrome patients, zebrafish sf3b1 mutants develop a macrocytic anemia-like phenotype due to a block in maturation at a late progenitor stage. [Exp Hematol] Abstract

CLINICAL RESEARCH

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia

Researchers conducted this retrospective study of 36 children (38 transplants) who received haploidentical hematopoietic stem cell transplantation (HSCT) from human leucocyte antigen (HLA)-mismatched related donors between July 2002 and November 2013 at five HSCT centers in China, including 17 cases that were 5/6 HLA matched and 21 that were 4/6 or 3/6 HLA matched. [Br J Haematol] Abstract

Haploidentical Hematopoietic Stem Cell Transplantation in Children with High-Risk Hematologic Malignancies: Outcomes with Two Different Strategies for GvHD Prevention. Ex Vivo T-Cell Depletion and Post-Transplant Cyclophosphamide: 10 Years of Experience at a Single Center

Forty patients with high-risk hematologic malignancies, median age nine years, underwent haploidentical-HSCT from April 2005 to April 2015. Seventeen patients were transplanted with CD3-depleted PBSCs by negative selection following a reduced-intensity conditioning regimen (RIC), and 23 patients received T-cell-replete PBSCs followed by post-transplantation cyclophosphamide after myeloablative conditioning or RIC. [Bone Marrow Transplant] Abstract

Late Effects Following Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning

Scientists describe the late effects in 102 consecutive patients surviving a minimum of five years (median follow-up 12.9 years) post cord blood transplantation. [Biol Blood Marrow Transplant] Abstract

Wilms Tumor 1 Mutations In The Pathogenesis Of Acute Myeloid Leukemia

The authors review the current status of the field and its therapeutic and prognostic implications in acute myeloid leukemia. [Haematologica] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Celator Pharmaceuticals^® Presented Phase III Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ (CPX-351) Significantly Improved Overall Survival

Celator Pharmaceuticals, Inc. announced results from its Phase III trial of VYXEOS™ Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia. [Press release from Celator Pharmaceuticals Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, Chicago] Press Release

Kiadis Pharma Announces Its Decision to File for Marketing Authorization with the European Medicines Agency (EMA) for ATIR101™ in Blood Cancers

Kiadis Pharma N.V. announced a regulatory strategy update that, based on positive Phase II data, it has taken the decision to submit a marketing authorization application to the EMA for its lead product ATIR101™ for use in blood cancers to reduce relapse rates, transplant related mortality and graft-versus-host-disease in the context of a hematopoietic stem cell transplantation using a haploidentical donor. [Kiadis Pharma N.V.] Press Release

Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000 its Lead Compound in the Treatment of Chronic Myeloid Leukemia (CML)

Escend Pharmaceuticals, Inc. announced that its lead compound, ES-3000, has received orphan drug designation from the U.S. FDA for the treatment of CML. [Escend Pharmaceuticals, Inc. (PR Newswire Association LLC.)] Press Release

NEW Gordon Research Conference – Tissue Niches & Resident Stem Cells in Adult Epithelia
August 7-12, 2016
Hong Kong, China

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Postdoctoral Researcher – Hematology and Oncology (Hannover Medical School)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

Technical Sales Representative (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Novartis)

Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.